Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets prim

[News]

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

More... (http://www.news-medical.net/news/20100317/Abraxis-BioSciences-Phase-3-trial-comparing-ABRAXANE-with-Taxol-injection-meets-primary-endpoint.aspx)